Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | ROR2 |
| Gene Name: | ROR2 |
| Protein Full Name: | Tyrosine-protein kinase transmembrane receptor ROR |
| Alias: | EC 2.7.10.1; Neurotrophic tyrosine kinase, receptor-related 2; NTRKR2 |
| Mass (Da): | 104757 |
| Number AA: | 943 |
| UniProt ID: | Q01974 |
| Locus ID: | 4920 |
| COSMIC ID: | ROR2 |
| Gene location on chromosome: | 9q22.31 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 20592 |
| Percent of cancer specimens with mutations: | 1.4 |
| General distribution of mutations: | Multi-site |
| Location of most mutations: | Broad distribution of mutation sites with many point mutations across entire protein, but no complex mutations, insertions or deletions. |
| Normal role description: | ROR2 is a receptor tyrosine kinase which may have a role in early cartilage and growth plate development. ROR2 expression is generally highest during embryonic development and will gradually decrease as cells terminally differentiate. Wnt5a has been identified to utilize ROR2 as a co-receptor for non-canonical Wnt signalling. Aberrant expression of ROR2 has been implicated in gastric, osteosarcoma, mestatic melanoma, prostate, renal cell and squamous cell carcinomas. Increased expression of ROR2 was correlated with increased metastasis. In prostate, osteosarcomas and metastatic melanomas, Wnt5a/ROR2 receptor complex formation was implicated as the mechanism for cancer progression. ROR2 seems to function as an oncogene. Primarily mis-sense mutations of ROR2 have been identified in tumours but their functional effect has not been well characterized. |
| Commentary on involvement of protein in cancer: | Less than 3% mutations in breast, CNS, large intestine and lung cancer. |